English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17939/22958 (78%)
Visitors : 7383784      Online Users : 77
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24914


    Title: Baseline factors identified for the prediction of good responders in patients with end-stage diffuse coronary artery disease undergoing intracoronary CD34+cell therapy
    Authors: Sung, PH;Chiang, HJ;Li, YC;Chiang, JY;Chu, CH;Shao, PL;Lee, FY;Lee , MS;Yip , HK
    Keywords: CD34+cell therapy;Good responders;Diffuse coronary artery disease;Refractory angina;Left ventricular ejection fraction
    Date: 2020
    Issue Date: 2022-08-09T08:10:03Z (UTC)
    Publisher: BMC
    Abstract: BackgroundTreating patients with end-stage diffuse coronary artery disease (EnD-CAD) unsuitable for coronary intervention remains a clinical challenge. They usually express refractory angina and have a high risk of mortality. Although growing data have indicated cell therapy is an alternative solution to medical or invasive therapy, there are still lacking useful markers to predict whether heart function will improve in the EnD-CAD patients who underwent circulatory-derived CD34+ cell therapy. By utilizing the baseline variables and results from our previous phase I/II clinical trials, the aim of this study tried to elucidate the variables predictive of the good response to CD34+ cell therapy.MethodsThis retrospective study included 38 patients in phase I clinical trial (2011-2014), and 30 patients in phase II clinical trial (2013-2017). These patients were categorized into good responders and non-responders according to their 1-year improvement of LVEF >= 7.0% or <7.0% after intracoronary CD34+ cell therapy. Univariate and multivariate logistic regression models were performed to identify potential independent predictors of a good responder to cell therapy, followed by Hosmer-Lemeshow (H-L) test for goodness of fit and prediction power.ResultsAmong baseline data, multivariate analysis demonstrated that the history of a former smoker was independently predictive of good responders (p =0.006). On the other hand, male gender, the baseline Canadian Cardiovascular Society angina score<greater than or equal to>3, and grades of LV diastolic dysfunction >= 2 were significantly negative predictors of good responders (all p <0.01). After administration of subcutaneous granulocyte-colony stimulating factor (G-CSF), a higher post-G-CSF neutrophil count in addition to the above four baseline variables also played crucial roles in early prediction of good response to CD34+ cell therapy for EnD-CAD (all p <0.03). The H-L test displayed a good prediction power with sensitivity 83.3%, specificity 85.3%, and accuracy 84.4%.ConclusionsUsing the results of our phase I/II clinical trials, previous smoking habit, female sex, lower grades of angina score, and diastolic dysfunction were identified to be independently predictive of good response to CD34+ cell therapy in the patients with EnD-CAD.Trial registrationThis is a retrospective analysis based on phase I (ISRCTN72853206) and II (ISRCTN26002902) clinical trials.
    URI: http://dx.doi.org/10.1186/s13287-020-01835-z
    https://www.webofscience.com/wos/woscc/full-record/WOS:000557708100005
    https://ir.csmu.edu.tw:8080/handle/310902500/24914
    Relation: STEM CELL RESEARCH & THERAPY ,2020 ,v11 ,issue 1
    Appears in Collections:[中山醫學大學研究成果] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML178View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback